Vaxcyte, Inc. PCVX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -25.6%-5.2pp | -20.4%+16.3pp | -36.7%-0.6pp | -36.1%-4.3pp | |
| Return on assets | -23.5%-4.7pp | -18.9%+14.5pp | -33.3%+0.3pp | -33.6%-5.7pp | |
| Return on invested capital | -32.9%-3.4pp | -29.5%+63.4pp | -92.9%+33.3pp | -126.3%— | |
| Liquidity | |||||
| Current ratio | 7.9×-4.8× | 12.8×+5.2× | 7.5×-15.7× | 23.3×+14.3× | |
| Quick ratio | 7.9×-4.8× | 12.8×+5.2× | 7.5×-15.7× | 23.3×+14.3× | |
| Cash ratio | 0.9×-1.9× | 2.8×0.0× | 2.7×-17.9× | 20.6×+18.2× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $19.73-27.2% | $27.10+112% | $12.77-13.1% | $14.70+169% | |
| Valuation | |||||
| Market capitalization | $6.04B-40.8% | $10.2B+70.4% | $5.99B+64.4% | $3.64B+166% | |
| Enterprise value | $5.98B-39.5% | $9.88B+75.9% | $5.62B+98.9% | $2.82B+115% | |
| Price / book | 2.2×-0.8× | 3.1×-1.7× | 4.8×+1.0× | 3.8×-1.0× | |
| Free cash flow yield | -11.1%-6.4pp | -4.7%+0.6pp | -5.2%-0.4pp | -4.8%+4.5pp | |
| Earnings yield | -12.7%-8.1pp | -4.5%+2.2pp | -6.7%-0.6pp | -6.1%+1.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Vaxcyte, Inc.'s ratios come from?
- Every ratio is computed from Vaxcyte, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.